XTER:SRT (Germany)
Business Description
Sartorius AG
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Compare
Compare
Traded in other countries / regions
SRT3.Austria
•
SRT.Germany
•
SRT3.Mexico
•
SRT3.Switzerland
•
0NIQ.UK
•
SARTF.USA
Description
Sartorius AG is the leading provider of biopharmaceutical fermentation and fluid management. In 2020, the bioprocess division contributed 76% to total revenue and the lab division the remaining 24%. The bioprocess division is traded as a separate company, Sartorius Stedim Biotech. Sartorius AG has a 74% ownership of this subsidiary with 85% voting control. In addition to biomanufacturing equipment and consumables, Sartorius offers a wide range of products for general lab use, such as scales, pipettes, and filtration equipment. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (40% of 2020 sales), the Americas (35%), and Asia-Pacific (25%). Sartorius employs over 10,000 people and has operations in more than 30 countries.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.27 | |||||
| Debt-to-Equity | 1.27 | |||||
| Debt-to-EBITDA | 1.77 | |||||
| Interest Coverage | 106.16 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 5.39 | |||||
| Beneish M-Score | -2.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 30.1 | |||||
| 3-Year EBITDA Growth Rate | 32.4 | |||||
| 3-Year EPS without NRI Growth Rate | 31.3 | |||||
| 3-Year FCF Growth Rate | 243 | |||||
| 3-Year Book Growth Rate | 19.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 13.76 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 18.58 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.75 | |||||
| 9-Day RSI | 54.59 | |||||
| 14-Day RSI | 56.82 | |||||
| 6-1 Month Momentum % | 1.61 | |||||
| 12-1 Month Momentum % | -38.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.24 | |||||
| Quick Ratio | 0.58 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 176.03 | |||||
| Days Sales Outstanding | 42.5 | |||||
| Days Payable | 101.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.32 | |||||
| Dividend Payout Ratio | 0.18 | |||||
| 3-Year Dividend Growth Rate | 11.9 | |||||
| Forward Dividend Yield % | 0.32 | |||||
| 5-Year Yield-on-Cost % | 0.46 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.54 | |||||
| Operating Margin % | 27.13 | |||||
| Net Margin % | 12.9 | |||||
| ROE % | 36.76 | |||||
| ROA % | 8.7 | |||||
| ROIC % | 15.87 | |||||
| ROC (Joel Greenblatt) % | 57.08 | |||||
| ROCE % | 21.9 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 53.62 | |||||
| Forward PE Ratio | 43.29 | |||||
| PE Ratio without NRI | 52.53 | |||||
| Shiller PE Ratio | 142.29 | |||||
| Price-to-Owner-Earnings | 172.35 | |||||
| PEG Ratio | 2.04 | |||||
| PS Ratio | 6.91 | |||||
| PB Ratio | 16.1 | |||||
| Price-to-Free-Cash-Flow | 115.48 | |||||
| Price-to-Operating-Cash-Flow | 37.65 | |||||
| EV-to-EBIT | 31.58 | |||||
| EV-to-Forward-EBIT | 25.4 | |||||
| EV-to-EBITDA | 24.84 | |||||
| EV-to-Forward-EBITDA | 21.83 | |||||
| EV-to-Revenue | 7.65 | |||||
| EV-to-Forward-Revenue | 7.18 | |||||
| EV-to-FCF | 128.49 | |||||
| Price-to-Projected-FCF | 7.18 | |||||
| Price-to-DCF (Earnings Based) | 1.4 | |||||
| Price-to-DCF (FCF Based) | 8.47 | |||||
| Price-to-Median-PS-Value | 1.68 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.13 | |||||
| Earnings Yield (Greenblatt) % | 3.17 | |||||
| Forward Rate of Return (Yacktman) % | 20.71 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,880.422 | ||
| EPS (TTM) (€) | 7.31 | ||
| Beta | 0.11 | ||
| Volatility % | 52.14 | ||
| 14-Day RSI | 56.82 | ||
| 14-Day ATR (€) | 15.373653 | ||
| 20-Day SMA (€) | 382.025 | ||
| 12-1 Month Momentum % | -38.46 | ||
| 52-Week Range (€) | 276.5 - 834 | ||
| Shares Outstanding (Mil) | 68.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sartorius AG Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||